Autolus Therapeutics plc Banner Image

Autolus Therapeutics plc

  • Ticker AUTL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Autolus Therapeutics plc Logo Image
  • 201-500 Employees
  • Based in London, England
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defenseMore mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
4.7 / 5.0 (76)

Autolus Therapeutics plc reports have an aggregate usefulness score of 4.7 based on 76 reviews.

Autolus Therapeutics plc

Most Recent Annual Report

Autolus Therapeutics plc
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Autolus Therapeutics plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!